Eiger BioPharmaceuticals, Inc.

OTCPK:EIGR.Q Rapport sur les actions

Capitalisation boursière : US$12.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Eiger BioPharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de Eiger BioPharmaceuticals ont diminué à un taux annuel moyen de -9.7%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en à 33.8% par an. Les revenus ont augmenté de en à un taux moyen de 59.9% par an.

Informations clés

-9.71%

Taux de croissance des bénéfices

15.17%

Taux de croissance du BPA

Biotechs Croissance de l'industrie17.04%
Taux de croissance des recettes59.85%
Rendement des fonds propresn/a
Marge nette-475.26%
Dernière mise à jour des bénéfices31 Dec 2023

Mises à jour récentes des performances passées

Recent updates

Article d’analyse • Apr 01

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders that were waiting for something to happen have been dealt a...
Article d’analyse • Jan 04

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders won't be pleased to see that the share price has had a very...
Article d’analyse • Dec 20

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

The latest analyst coverage could presage a bad day for Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ), with the...
Article d’analyse • Nov 09

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Shareholders in Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) may be thrilled to learn that the analysts have just...
Article d’analyse • Oct 06

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Seeking Alpha • Oct 05

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a biotech focused on rare and ultra-rare diseases, slipped ~20% pre-market Wednesday after announcing it would not seek an emergency use authorization (EUA) application in the U.S. for COVID-19 therapy peginterferon lambda. The decision followed a pre-EUA meeting the company had requested from the FDA. The agency denied the request citing issues in an investigator-sponsored trial designed to assess different therapeutic agents, including peginterferon, in non-hospitalized patients with mild-to-moderate COVID-19. FDA has determined that “any authorization request based on these data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic,” the company said. Instead, the agency has suggested that EIGR consider requesting an end-of-Phase 2 meeting to run a company-sponsored pivotal trial targeted at a Biologics License Application (BLA). EIGR is weighing the next steps, including strategic options to advance peginterferon lambda against respiratory viral agents, including COVID-19. Read: In September, the FDA updated its COVID-19 test policy to cut the number of reviews of EUA requests for diagnostic tests.
Seeking Alpha • Sep 06

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

The shares of commercial-stage biotech Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) fell ~21% in the pre-market Tuesday after the company announced that the FDA is uncertain about the regulatory path for COVID-19 therapy peginterferon lambda. The update comes after the company's meeting with the regulator regarding the Phase 3 TOGETHER study for peginterferon lambda aimed at its emergency use authorization (EUA). Following the meeting, the FDA has indicated its uncertainty if the company can meet the requirements for a EUA submission for peginterferon lambda. However, EIGR remains in talks with the FDA as the regulator indicated its intention to consider any new data from the TOGETHER trial to support a EUA while the company plans to further develop the candidate in COVID-19.
Seeking Alpha • Jul 26

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for the treatment of patients with Hepatitis Delta Virus are expected by end of 2022. In March of 2022, a single dose of peginterferon Lambda for Covid-19, reduced the risk of hospitalization or ER visits greater than 6 hours by 50% in a predominantly vaccinated population. An Emergency Use Authorization filing from Eiger BioPharmaceuticals to the FDA for peginterferon Lambda for Covid-19 is possible in 2022. Eiger BioPharmaceuticals (EIGR) is a great speculative biotech play to look into. That's because it has a major catalyst for investors to look forward to at the end of 2022. This would be the readout of the phase 3 D-LIVR study, which is using Lonafarnib for the treatment of patients with Hepatitis Delta Virus ((HDV)). There is potential here to eventually possibly obtain approval for two combinations. These combinations include Lonafarnib and ritonavir and in combination with peginterferon alfa. In addition, this biotech had already received European approval for its treatment Zokinvy (Lonafarnib) for the treatment of patients with progeria. It is the first and only treatment approved in Europe for this specific indication. In addition, another possible catalyst would be Emergency Use Authorization (EUA) for Peginterferon Lambda for Covid-19 infection. The company is engaging with the FDA and intends to submit an EUA application along with the full set of results from the TOGETHER study. It was done in a predominantly vaccinated patient population, so it remains to be seen how well it does if it is ultimately approved. Regardless, I believe EUA could act as a trade opportunity. These are the reasons why I believe that Eiger BioPharmaceuticals is a great speculative biotech play to look into. Lonafarnib Catalyst Expected End Of 2022 Lonafarnib is in clinical development for the treatment of patients with Hepatitis Delta Virus. Hepatitis Delta Virus ((HDV)) or Hepatitis D is a very small circular RNA virus. It is one of the smallest types of virus that infects humans. However, right off the bat I will tell you that it is rare. Why is it rare? That's because in order for the HDV to infect someone, they also have to be carrying Hepatitis B (HBV). That's right, HDV needs HBV in order to infect a person. That's the only way HDV can replicate in liver cells. Those who may be at risk of getting HDV are those who have gone through many blood transfusions and those who are intravenous types of drug abusers. Symptoms of those who have this virus are as follows: Abdominal type pain Nausea Fatigue Being rare, there are roughly only about less than 200,000 people in the United States who have it. Eiger estimates that an HDV product could be about a >$1 billion per year market opportunity. The good news is that this program is already ongoing and still enrolling patients. This is known as the phase 3 D-LIVR study, which is estimated to enroll about 400 patients total. At least 300 patients will be treated with Lonafarnib. There are going to be two arms in the study as follows: All oral arm of LNF (lonafarnib) boosted with RTV (ritonavir) LNF boosted with RTV combined with pegylated interferon-alfa (PEG IFN-alfa) Each of the 2 arms above are going to be compared to placebo. That means in order for this study to be successful, it just needs to meet the primary endpoint compared to placebo. The composite primary endpoint is twofold as follows: Compare composite virologic and biochemical response rate at end of treatment ((EOT)) in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir versus patients who receive placebo (over 48 weeks) Compare composite virologic and biochemical response rate at end of EOT in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir and 180 mcg QW PEG IFN-alfa-2a (over 48 weeks)
Seeking Alpha • Jul 20

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Eiger BioPharmaceuticals (NASDAQ:EIGR) on Wednesday said the European Commission had granted a marketing authorization to its treatment Zokinvy (lonafarnib) for progeria, which is a progressive genetic disorder that causes accelerated aging. The specific indication for which Zokinvy was approved was as a breakthrough therapy in children and young adults with Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. The European approval for Zokinvy is valid in all 27 EU member states as well as Iceland, Liechtenstein and Norway. EIGR says Zokinvy is the first and only treatment approved in Europe for progeria. The therapy was approved by the U.S. FDA in 2020. EIGR stock +2.8% to $8.73 in early trading.

Ventilation des recettes et des dépenses

Comment Eiger BioPharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

OTCPK:EIGR.Q Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 Dec 2316-752562
30 Sep 2315-872969
30 Jun 2315-963077
31 Mar 2315-973274
31 Dec 2213-972975
30 Sep 2214-932775
30 Jun 2213-892671
31 Mar 2211-862568
31 Dec 2112-342464
30 Sep 219-312359
30 Jun 216-242250
31 Mar 214-212146
31 Dec 200-652142
30 Sep 200-632041
30 Jun 200-661945
31 Mar 200-681848
31 Dec 190-701752
30 Sep 190-701752
30 Jun 190-681651
31 Mar 190-611544
31 Dec 180-521437
30 Sep 180-471333
30 Jun 180-391226
31 Mar 180-401128
31 Dec 170-421230
30 Sep 170-441331
30 Jun 170-471333
31 Mar 170-491336
31 Dec 160-471333
30 Sep 160-411327
30 Jun 160-331021
31 Mar 160-22813
31 Dec 150-1358
30 Sep 150-725
31 Dec 140-211

Des revenus de qualité: EIGR.Q n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: EIGR.Q n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: EIGR.Q n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 9.7% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de EIGR.Q au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: EIGR.Q n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 43% ).

Rendement des fonds propres

ROE élevé: Le passif EIGR.Q dépasse son actif, il est donc difficile de calculer son rendement des capitaux propres.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2024/10/02 08:27
Cours de l'action en fin de journée2024/10/01 00:00
Les revenus2023/12/31
Revenus annuels2023/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Eiger BioPharmaceuticals, Inc. est couverte par 11 analystes. 0 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Madhu KumarBaird
Brian SkorneyBaird
Madhu KumarB. Riley Securities, Inc.